Influence of Antidrug Antibodies on Plectasin Efficacy and Pharmacokinetics
- 1 November 2009
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 53 (11) , 4794-4800
Abstract
Plectasin is a 4.4-kDa antimicrobial peptide with the potential to be a treatment of infections caused by gram-positive bacteria. Since plectasin is a large molecule compared to conventional antibiotics, the development of antidrug antibodies (ADAs) could be anticipated. The immunogenic properties of plectasin were assessed through immunization studies. In mice treated for 5 days with one to two daily subcutaneous doses of plectasin, no antibody response was observed. If the animals were immunized again, after a rest period, low levels of antibodies developed in approximately half the animals. Additionally, mice were immunized with plectasin in Freund's incomplete adjuvant (FIA). Ninety-two percent of these mice developed ADAs after repeated immunizations, with two-thirds having high levels of antibodies. An agar diffusion bioassay showed that sera from animals immunized with plectasin did not inhibit the efficacy of the drug, while hyperimmune sera from animals in which an immune response was provoked by immunization with plectasin in FIA reduced the efficacy of plectasin at the lowest concentration tested. Studies in the murine peritonitis model showed an excellent efficacy of plectasin for the treatment of Streptococcus pneumoniae infections both in naïve animals and in animals with ADAs. No difference in bacterial counts was seen when the animals were treated with plectasin at 2.5 mg/kg of body weight, a dose below the expected therapeutic level. When animals were treated with plectasin at 0.625 mg/kg, the effect was reduced but not neutralized in animals with high levels of ADAs. No animals showed signs of hypersensitivity or injection site reactions toward plectasin, and the half-life of the compound did not vary between animals with and without antibodies.Keywords
This publication has 31 references indexed in Scilit:
- Neutralizing antibodies to biological therapiesNeurology, 2007
- A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugsNature Biotechnology, 2007
- Antimicrobial and host-defense peptides as new anti-infective therapeutic strategiesNature Biotechnology, 2006
- Antibacterial peptides for therapeutic use: obstacles and realistic outlookCurrent Opinion in Pharmacology, 2006
- Emergence of multidrug-resistant Streptococcus pneumoniae: report from the SENTRY Antimicrobial Surveillance Program (1999–2003)Diagnostic Microbiology and Infectious Disease, 2006
- Scientific and regulatory considerations on the immunogenicity of biologicsTrends in Biotechnology, 2006
- Validation of immunoassays used to assess immunogenicity to therapeutic monoclonal antibodiesJournal of Pharmaceutical and Biomedical Analysis, 2005
- The importance of measuring IFNβ bioactivity: Monitoring in MS patients and the effect of anti-IFNβ antibodiesJournal of Neuroimmunology, 2005
- A Review of Antimicrobial Peptides and Their Therapeutic Potential as Anti-Infective DrugsCurrent Eye Research, 2005
- Phage lytic enzymes as therapy for antibiotic-resistant Streptococcus pneumoniae infection in a murine sepsis modelJournal of Antimicrobial Chemotherapy, 2003